Improved and composite biomarkers in the future could not only help to evaluate the functional activity of c-MET protein accurately but also use alternative indicators such as MET gene alterations and EGFR mutations to precisely determine the type of NSCLC (105). This evidence concerns the gene MET and non-small cell lung carcinoma.